NEW YORK, May 26, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted…


Previous articleHealing Trip Tales: One Vet’s Ibogaine & 5-MeO-DMT Experience for PTSD and TBI
Next articleAlgernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke